Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
27 NC counties and 1 VA county are under alert, including Mecklenburg, VA and Northampton counties.
Just In
Kentucky Wildcats topple Duke Blue Devils 77-72 in hard-fought battle
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Context Therapeutics Inc
(NQ:
CNTX
)
2.050
+0.010 (+0.49%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Context Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
November 06, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics to Participate in Upcoming Investor Conferences in November
October 23, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 22, 2024
Via
Benzinga
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
October 16, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
September 23, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
September 04, 2024
The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
August 07, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
August 01, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
July 10, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight
May 30, 2024
If you believe in chasing the winners higher, here are three hypergrowth stocks that may provide Nvidia-like gains.
Via
InvestorPlace
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
May 22, 2024
Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them.
Via
InvestorPlace
CNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024
May 08, 2024
CNTX stock results show that Context Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
May 08, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 02, 2024
Via
Benzinga
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
May 02, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces $100 Million Private Placement
May 02, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
April 01, 2024
Important Regulatory Milestone Supports Next Phase of CTIM-76 Development
From
Context Therapeutics Inc.
Via
GlobeNewswire
CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023
March 21, 2024
CNTX stock results show that Context Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
March 21, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
January 12, 2024
Via
Benzinga
Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 15, 2023
Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results. Quanex Building Products shares fell 10.7% to...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
December 15, 2023
Via
Benzinga
Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday
December 15, 2023
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday. Here are some other big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 08, 2023
Via
Benzinga
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
November 09, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 31, 2023
Via
Benzinga
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
October 31, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
October 23, 2023
Via
ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 02, 2023
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.